Cogent Biosciences Dividends and Buybacks
Dividend criteria checks 0/6
Cogent Biosciences does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-26.2%
Buyback Yield
| Total Shareholder Yield | -26.2% |
| Future Dividend Yield | 0% |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Here's Why We're Watching Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation
Dec 18
Cogent Biosciences (NASDAQ:COGT) Is In A Good Position To Deliver On Growth Plans
Sep 04Cogent Biosciences: Inflection Year Directly Ahead
Jun 23Cogent Biosciences (NASDAQ:COGT) Is In A Good Position To Deliver On Growth Plans
May 22Cogent Biosciences: Stock Soars On Cash Injection Ahead Of Major Data Catalyst
Feb 14Here's Why We're Watching Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation
Nov 27Is Cogent Biosciences (NASDAQ:COGT) In A Good Position To Invest In Growth?
Jun 20Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation
Mar 05Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation
Nov 18Cogent Biosciences: What's Ahead
Sep 13Cogent Biosciences: APEX Data Was Interesting, But We Need More
Jun 26Is Cogent Biosciences (NASDAQ:COGT) In A Good Position To Invest In Growth?
Jun 10Cogent Biosciences names new chief legal officer
May 03What You Need To Know About Cogent Biosciences, Inc.'s (NASDAQ:COGT) Investor Composition
Mar 17Cogent Biosciences gets Piper Sandler nod on Kiq acquisition
Dec 23Cogent Biosciences prices upsized $100M equity offering
Dec 02Cogent Bio launches $60M equity offering, shares down 7%
Nov 30Cogent Bio reports data from PLX9486 combo trial in GIST patients
Nov 18Cogent Biosciences EPS misses by $4.91
Nov 09Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if COGT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if COGT's dividend payments have been increasing.
Dividend Yield vs Market
| Cogent Biosciences Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (COGT) | n/a |
| Market Bottom 25% (US) | 1.5% |
| Market Top 25% (US) | 4.5% |
| Industry Average (Biotechs) | 2.5% |
| Analyst forecast (COGT) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate COGT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate COGT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate COGT's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as COGT has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/03 20:57 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Cogent Biosciences, Inc. is covered by 16 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Colleen Kusy | Baird |
| Joel Beatty | Baird |
| David Lebowitz | Citigroup Inc |